Bicara Therapeutics Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Bicara Therapeutics Inc. (BCAX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $550.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-11
- Bicara Therapeutics Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $277.00K, a 31.28% increase year-over-year.
- Bicara Therapeutics Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $273.00K, a 97.83% increase year-over-year.
- Bicara Therapeutics Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $249.00K, a 266.18% increase year-over-year.
- Bicara Therapeutics Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $211.00K, a 219.70% increase year-over-year.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month |
|---|---|---|---|
| 2026-06-30 | $277.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $550.00K 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $273.00K 10-Q · filed 2026-05-11 | ||
| 2025-09-30 | $249.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $460.00K derived: sum of 2 quarters · filed 2026-08-11 | $598.00K 10-Q · filed 2025-11-10 |
| 2025-06-30 | $211.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $349.00K 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $138.00K 10-Q · filed 2026-05-11 | ||
| 2024-09-30 | $68.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $134.00K derived: sum of 2 quarters · filed 2025-11-10 | $199.00K 10-Q · filed 2025-11-10 |
| 2024-06-30 | $66.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $131.00K 10-Q · filed 2025-08-12 | |
| 2024-03-31 | $65.00K 10-Q · filed 2025-05-13 | ||
| 2023-09-30 | $26.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |